Journal
CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume 94, Issue 3, Pages 324-328Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/clpt.2013.103
Keywords
-
Categories
Funding
- National Institutes of Health (NIH)
- NIH [2U19GM061390, R24 GM61374, MH92758, U19 HL065962, U01 GM092666, U01 HL0105918]
- Epilepsy Research UK [P1105] Funding Source: researchfish
- National Institute for Health Research [NF-SI-0512-10064] Funding Source: researchfish
Ask authors/readers for more resources
Human leukocyte antigen B (HLA-B) is a gene that encodes a cell surface protein involved in presenting antigens to the immune system. The variant allele HLA-B*15:02 is associated with an increased risk of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in response to carbamazepine treatment. We summarize evidence from the published literature supporting this association and provide recommendations for the use of carbamazepine based on HLA-B genotype (also available on PharmGKB: http://www.pharmgkb.org). The purpose of this article is to provide information to allow the interpretation of clinical HLA-B*15:02 genotype tests so that the results can be used to guide the use of carbamazepine. The guideline provides recommendations for the use of carbamazepine when HLA-B*15:02 genotype results are available. Detailed guidelines regarding the selection of alternative therapies, the use of phenotypic tests, when to conduct genotype testing, and cost-effectiveness analyses are beyond the scope of this document. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines are published and updated periodically on the PharmGKB website at (http://www.pharmgkb.org).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available